-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cathy Scangarella to Join the Advisory Board of Xcelerate, Inc.
Cathy Scangarella to Join the Advisory Board of Xcelerate, Inc.
MAULDIN, SC / ACCESSWIRE / June 7, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) today announced that Cathy Scangarella has accepted an invitation to join its Advisory Board effective immediately.
Cathy Scangarella is the Chief Business Development Officer and sector lead for Life Sciences at Choose New Jersey, New Jersey's leading nonprofit economic development organization. Cathy leads the business development team and oversees the organization's national and international lead generation, prospect management and business development strategy for all key industries. She also oversees the Choose New Jersey India and Europe offices and has enhanced New Jersey's relationships with key multipliers and trade associations around the globe.
During her tenure at Choose New Jersey, Cathy developed a new tactical business development approach for business attraction efforts to concentrate efforts in key domestic and international markets. She had a leading role in the strategic planning of Choose New Jersey's business attraction missions to Israel, Germany, Ireland, and India. While abroad, she helped established international university collaborations and industry partnerships for many of New Jersey's research universities including Rutgers University, Princeton University, New Jersey City University and Rowan University. Notable clients include Ascelia Pharma, BAP Pharma, CSL Plasma, Fordoz Pharmaceuticals, Minerva Biolabs and Biofarma US.
Cathy is a veteran of New Jersey State government, having served six administrations. With over 25 years of experience in marketing, outreach, and business development, she has served as Deputy Chief of Staff to Lt. Governor Guadagno, Director of State Marketing at the New Jersey Business Action Center, Director of Outreach Programs for Business Retention & Attraction at the New Jersey Economic Development Authority, and Vice President of Marketing & Communications for the New Jersey Commerce Commission. Cathy is a member of the Research With New Jersey Advisory Board, the Innovation New Jersey Coalition, and an E&Y Entrepreneur of the Year Judge 2019-2021. She was named among the ROI-NJ Influencers: Women in Business - Economic Development in 2021.
Cathy holds a Bachelor of Science degree in Business Administration with a concentration in Marketing from Ramapo College of New Jersey.
"Cathy brings a valued new skill set to our Advisory Board," said Michael O'Shea, Xcelerate's CEO. "Cathy's' experience business development, along with her years of relationships with research institutions, should prove invaluable to Xcelerate as we begin to advance the development of the portfolio of patents recently acquired from HS Pharmaceuticals as well as our continued development of patentable med-tech. "
"I would like to thank our partners and investors for their continued support as we continue to execute on our business plan"
For more information please contact info@xcelerate.global
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
SOURCE: Xcelerate, Inc.
View source version on accesswire.com:
MAULDIN, SC / ACCESSWIRE / June 7, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) today announced that Cathy Scangarella has accepted an invitation to join its Advisory Board effective immediately.
南卡罗来纳州莫尔丁,ACCESSWIRE/2022年6月7日/Xcelerate,Inc.(场外交易市场代码:XCRT)今天宣布,Cathy Scangarella已接受邀请加入其顾问委员会,立即生效。
Cathy Scangarella is the Chief Business Development Officer and sector lead for Life Sciences at Choose New Jersey, New Jersey's leading nonprofit economic development organization. Cathy leads the business development team and oversees the organization's national and international lead generation, prospect management and business development strategy for all key industries. She also oversees the Choose New Jersey India and Europe offices and has enhanced New Jersey's relationships with key multipliers and trade associations around the globe.
凯西·斯坎加雷拉是新泽西州领先的非营利性经济发展组织Choose New Jersey的首席业务发展官和生命科学部门负责人。凯西领导着业务开发团队,并监督该组织针对所有关键行业的国内和国际领先地位产生、前景管理和业务发展战略。她还负责管理Choose新泽西州、印度和欧洲办事处,并加强了新泽西州与全球重要的倍增公司和贸易协会的关系。
During her tenure at Choose New Jersey, Cathy developed a new tactical business development approach for business attraction efforts to concentrate efforts in key domestic and international markets. She had a leading role in the strategic planning of Choose New Jersey's business attraction missions to Israel, Germany, Ireland, and India. While abroad, she helped established international university collaborations and industry partnerships for many of New Jersey's research universities including Rutgers University, Princeton University, New Jersey City University and Rowan University. Notable clients include Ascelia Pharma, BAP Pharma, CSL Plasma, Fordoz Pharmaceuticals, Minerva Biolabs and Biofarma US.
在新泽西州Choose任职期间,Cathy开发了一种新的战术性业务发展方法,以吸引业务,将精力集中在关键的国内和国际市场。她在Choose New Jersey赴以色列、德国、爱尔兰和印度的招商代表团的战略规划中发挥了领导作用。在国外期间,她帮助新泽西州的许多研究型大学建立了国际大学合作和行业合作伙伴关系,包括罗格斯大学、普林斯顿大学、新泽西城市大学和罗文大学。著名客户包括Ascelia Pharma、BAP Pharma、CSL等离子体、Fordoz制药公司、Minerva Biolabs和Biofarma US。
Cathy is a veteran of New Jersey State government, having served six administrations. With over 25 years of experience in marketing, outreach, and business development, she has served as Deputy Chief of Staff to Lt. Governor Guadagno, Director of State Marketing at the New Jersey Business Action Center, Director of Outreach Programs for Business Retention & Attraction at the New Jersey Economic Development Authority, and Vice President of Marketing & Communications for the New Jersey Commerce Commission. Cathy is a member of the Research With New Jersey Advisory Board, the Innovation New Jersey Coalition, and an E&Y Entrepreneur of the Year Judge 2019-2021. She was named among the ROI-NJ Influencers: Women in Business - Economic Development in 2021.
凯西是新泽西州政府的资深人士,曾在六届政府任职。她在营销、外联和业务开发方面拥有超过25年的经验,曾担任过瓜达尼奥副州长的副幕僚长,新泽西州商业行动中心州市场营销部的董事,新泽西州经济发展局商业保留和吸引外联计划的董事,以及新泽西州商务委员会营销和传播部副总裁。凯西是新泽西研究咨询委员会、新泽西创新联盟的成员,也是2019-2021年安永年度企业家评委。她被提名为ROI-NJ影响力人物:2021年商业中的女性-经济发展。
Cathy holds a Bachelor of Science degree in Business Administration with a concentration in Marketing from Ramapo College of New Jersey.
凯西拥有新泽西州拉马波学院工商管理学士学位,主修市场营销。
"Cathy brings a valued new skill set to our Advisory Board," said Michael O'Shea, Xcelerate's CEO. "Cathy's' experience business development, along with her years of relationships with research institutions, should prove invaluable to Xcelerate as we begin to advance the development of the portfolio of patents recently acquired from HS Pharmaceuticals as well as our continued development of patentable med-tech. "
Xcelerate的首席执行官Michael O‘Shea说:“Cathy为我们的顾问委员会带来了一套宝贵的新技能。随着我们开始推进最近从HS制药公司收购的专利组合的发展,以及我们对可专利医疗技术的持续开发,凯西的业务发展经验以及她与研究机构多年的关系将被证明对Xcelerate公司来说是无价的。“
"I would like to thank our partners and investors for their continued support as we continue to execute on our business plan"
我要感谢我们的合作伙伴和投资者在我们继续执行我们的商业计划时给予的持续支持。
For more information please contact info@xcelerate.global
欲了解更多信息,请联系info@xcelerate.global。
SAFE HARBOR
安全港
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
本新闻稿可能包含经修订的1934年证券交易法(“交易法”)第21E节所指的前瞻性信息,包括与公司、其董事或高级管理人员在以下方面的意图、信念或当前预期有关的所有不是历史事实的陈述:(1)公司的融资计划;(2)影响公司财务状况或经营结果的趋势;(3)公司的增长战略和经营战略;以及(4)宣布和支付股息。“可能”、“将”、“将”、“预期”、“估计”、“预期”、“相信”、“打算”以及类似的表述及其变体旨在识别前瞻性陈述。请投资者注意,任何此类前瞻性陈述都不是对未来业绩的保证,涉及风险和不确定性,其中许多风险和不确定性超出了公司的控制能力,实际结果可能与前瞻性陈述中预测的结果大不相同 由以下原因导致 各种因素。
SOURCE: Xcelerate, Inc.
资料来源:Xcelerate公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧